CTOs on the Move

Nipro Medical

www.nipro.com

 
Nipro provides premium renal medical devices, including dialyzers, bloodlines, AVF needles, as well as high-quality medical surgical products.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.nipro.com
  • 200, Crossing Blvd
    Bridgewater, NJ USA 08807
  • Phone: 908.393.7030

Executives

Name Title Contact Details

Similar Companies

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.

Auris Health

Auris is a robotic medical company led by Fred Moll, a pioneer in surgical robotics. Our technology represents the next era of medical innovation: flexible robotics that allow for the least invasive approach entry into the body through its natural open...

illumiPure

illumiPure’s patented Air Guardian and CleanWhite product solutions provide continuous and powerful disinfection to safely eradicate surface and air pathogens, as well as viruses, including SARS-CoV-2, the virus that causes COVID-19, while continuously...

Amplyx Pharmaceuticals

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.